SCHEMBL4365501

SCHEMBL4365501

O=C(NSC(=O)c1cc2ccccc2o1)Nc1cccc(OCCc2ccccc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.47
TSHR P16473 3/20 0.47
HPGD P15428 2/20 0.47
SIRT2 Q8IXJ6 4/20 0.47
NR1H4 Q96RI1 1/20 0.45
NPC1 O15118 7/20 0.44
RAB9A P51151 7/20 0.44
TP53 P04637 6/20 0.44
PKM P14618 3/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
EPHX2 P34913 1/20 0.43
MEN1 O00255 6/20 0.43
KMT2A Q03164 6/20 0.43
MAPT P10636 3/20 0.43
POLB P06746 1/20 0.43
SLC16A3 O15427 1/20 0.43
MAPK1 P28482 2/20 0.42
NLRP3 Q96P20 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2869820 0.85 NPC1 (0.44) SMN1; SMN2TSHRSIRT2NPC1RAB9A
SCHEMBL4366041 0.81 NPC1 (0.47) SMN1; SMN2TSHRNPC1RAB9ATP53
SCHEMBL4373587 0.81 NPC1 (0.47) SMN1; SMN2TSHRNPC1RAB9ATP53
SCHEMBL4365503 0.80 NPC1 (0.63) SMN1; SMN2TSHRHPGDNPC1RAB9A
SCHEMBL4375300 0.78 NPC1 (0.41) SMN1; SMN2TSHRNPC1RAB9ATP53
SCHEMBL10805699 0.75 SIRT2 (0.58) SIRT2NR1H4RAB9AEPHX2KMT2A
SCHEMBL14096098 0.72 NPC1 (0.66) SMN1; SMN2TSHRHPGDNPC1RAB9A
SCHEMBL2915616 0.71 SIRT2 (0.42) SIRT2EPHX2SIRT1SIRT3
SCHEMBL11128203 0.71 RAB9A (0.59) SMN1; SMN2TSHRSIRT2NR1H4NPC1
SCHEMBL4367642 0.71 RAB9A (0.48) SMN1; SMN2TSHRHPGDNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7476686-B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2009-01-13 US claimed
US-20060014836-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication CHEN DAWEI 2006-01-19 US claimed
EP-1562895-A1 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION Achillion Pharmaceuticals, Inc. (US) 2005-08-17 EP claimed
US-20040138205-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2004-07-15 US claimed
WO-2004046095-A1 SUBSTITUTED ARYL THIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2004-06-03 WO claimed
US-7476686-B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2009-01-13 US disclosed
US-7094807-B2 Substituted aryl thioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2006-08-22 US disclosed
US-20060014836-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication CHEN DAWEI 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138205-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication NAT1, PIGS, TPMT SMN1; SMN2 2545/4885TSHR 245/4885HPGD 3824/4885
US-20060014836-A1 Substituted aryl thioureas and related compounds; inhibitors of viral replication NAT1, PIGS, SLC10A1 SMN1; SMN2 2335/4885TSHR 130/4885HPGD 3743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.